echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Reduce the risk of death by 31%, the innovative treatment of cervical cancer terminates phase 3 clinical trials early

    Reduce the risk of death by 31%, the innovative treatment of cervical cancer terminates phase 3 clinical trials early

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Sanofi and Regeneron jointly announced that the PD-1 inhibitor Libtayo (cemiplimab) jointly developed by the two parties will be used as a monotherapy for the treatment of stage 3 patients with relapsed/metastatic cervical cancer.


    Cervical cancer is the fourth leading cause of cancer deaths in women in the world, and it most often occurs in women aged 35-44.


    Libtayo is a PD-1 inhibitor that enhances the anti-cancer immune response of T lymphocytes by blocking the binding of PD-1 and its ligand.


    In this open-label, multi-center phase 3 clinical trial, patients with recurrent/metastatic cervical cancer who had progressed after platinum-containing chemotherapy were treated with Libtayo or chemotherapy selected by the investigator.


    In the squamous cell carcinoma subgroup, Libtayo reduced the risk of death by 27%, while in the adenocarcinoma subgroup, Libtayo reduced the risk of death by 44%.


    Note: The original text has been deleted

    Reference materials:

    [1] PHASE 3 TRIAL OF LIBTAYO® (CEMIPLIMAB) MONOTHERAPY IN ADVANCED CERVICAL CANCER STOPPED EARLY FOR POSITIVE RESULT ON OVERALL SURVIVAL.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.